HerScan LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
HerScan LLC - overview
Established
2011
Location
Belleair Bluffs, FL, US
Primary Industry
Healthcare
About
HerScan LLC, based in the US, specializes in advanced breast ultrasound screening services, enhancing early detection of breast cancer, particularly for women with dense breast tissue, through comprehensive examinations. Founded in 2011 in Belleair Bluffs, US, HerScan LLC focuses on breast screening services. The company has conducted one deal, with the most recent being on December 31, 2025. The founder has not been specified.
HerScan specializes in providing advanced breast ultrasound screening services designed to enhance early detection of breast cancer, particularly in women with dense breast tissue. Their core offering consists of comprehensive breast ultrasound examinations performed by certified sonographers, followed by interpretation by board-certified radiologists. These screenings are intended to detect abnormalities that may not be visible through traditional mammography or physical exams alone, thus addressing the critical need for accessible, effective breast health care. HerScan operates mobile health screening events throughout the United States, with services available in various states, ensuring that women in diverse communities can access their offerings conveniently.
The target clientele for HerScan includes women of all ages, particularly those with dense breast tissue, who are seeking proactive solutions for their breast health. HerScan generates revenue primarily through direct-to-consumer transactions for breast ultrasound screenings, which are priced at an upfront cost of USD 295, with adjustments for certain states. The company operates on a straightforward payment model, collecting fees at the time of service and accepts various payment methods, including major credit and debit cards and certain FSA/HSA cards. The screening service includes a complete ultrasound of both breasts and the underarm area, along with secure access to results through an online portal.
This model allows HerScan to streamline the customer experience, with no need for a doctor's referral, making it an attractive option for women seeking timely access to vital breast health screenings. Additionally, HerScan offers a USD 20 military discount, reflecting their commitment to serving diverse segments of the population effectively. In 2025, HerScan plans to expand its mobile breast ultrasound screening services following an investment from Next Coast Legacy. The company aims to make testing more accessible and affordable as part of women's routine health care.
This investment will facilitate the enhancement of services and the potential expansion into new geographic markets, helping to reach more women in need of these critical screenings.
Current Investors
Next Coast Legacy
Primary Industry
Healthcare
Sub Industries
Clinics/Outpatient Services, Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment
Website
www.herscan.com
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
HerScan LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Growth | Completed | HerScan LLC | - |
Displaying 1 - 1 of 1

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.